Modern management of lymphocyte predominant Hodgkin lymphoma

British Journal of Haematology

Volumn 161, Issue 3, 2013, Pages 316-329

  Xing, Katharine H ^a   Savage, Kerry J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Advanced stage; Limited stage; Nodular lymphocyte predominant Hodgkin lymphoma; Outcome

Indexed keywords

BLEOMYCIN; CARMUSTINE; CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MALIGNANT TRANSFORMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT CANCER; SEX DIFFERENCE; T LYMPHOCYTE RICH B CELL LYMPHOMA; TREATMENT RESPONSE; WATCHFUL WAITING;

ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTE SUBSETS; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPH NODE EXCISION; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY; RISK; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876189837     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12244     Document Type: Article

References (61)

1. Al-Mansour, M., Connors, J.M., Gascoyne, R.D., Skinnider, B. & Savage, K.J. (2010) Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 793-799.
2. Anagnostopoulos, I., Hansmann, M.L., Franssila, K., Harris, M., Harris, N.L., Jaffe, E.S., Han, J., van Krieken, J.M., Poppema, S., Marafioti, T., Franklin, J., Sextro, M., Diehl, V. & Stein, H. (2000) European task force on lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood, 96, 1889-1899.
3. Ansquer, C., Hervouet, T., Devillers, A., de Guibert, S., Gastinne, T., Le Gouill, S., Garin, E., Moreau, A., Kraeber-Bodere, F. & Lamy, T. (2008) 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica, 93, 128-131.
4. Appel, B.E., Chen, L., Buxton, A., Wolden, S.L., Hodgson, D.C. & Nachman, J.B. (2012a) Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 59, 1284-1289.
5. Appel, B.E., Ehrlich, P., Chen, L., Hutchinson, R.E., Hodgson, D.C., Constine, L.S. & Schwartz, C.L. (2012b) Treatment of pediatric stage IA lymphocyte-predominant hodgkin lymphoma with surgical resection alone: a report from the children's oncology group. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 30 (Suppl. 1), Abstract 9524.
6. Biasoli, I., Stamatoullas, A., Meignin, V., Delmer, A., Reman, O., Morschhauser, F., Coiffier, B., Bosly, A., Divine, M. & Brice, P. (2010) Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer, 116, 631-639.
7. Bodis, S., Kraus, M.D., Pinkus, G., Silver, B., Kadin, M.E., Canellos, G.P., Shulman, L.N., Tarbell, N.J. & Mauch, P.M. (1997) Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. Journal of Clinical Oncology, 15, 3060-3066.
8. Bonadonna, G., Bonfante, V., Viviani, S., Di Russo, A., Villani, F. & Valagussa, P. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. Journal of Clinical Oncology, 22, 2835-2841.
9. Brune, V., Tiacci, E., Pfeil, I., Doring, C., Eckerle, S., van Noesel, C.J., Klapper, W., Falini, B., von Heydebreck, A., Metzler, D., Brauninger, A., Hansmann, M.L. & Kuppers, R. (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. The Journal of Experimental Medicine, 205, 2251-2268.
10. Burns, B.F., Colby, T.V. & Dorfman, R.F. (1984) Differential diagnostic features of nodular L & H Hodgkin's disease, including progressive transformation of germinal centers. The American Journal of Surgical Pathology, 8, 253-261.
11. Campbell, B.A., Voss, N., Woods, R., Gascoyne, R.D., Morris, J., Pickles, T., Connors, J.M. & Savage, K.J. (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer, 116, 3797-3806.
12. Canellos, G.P. & Mauch, P. (2010) What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? Journal of Clinical Oncology, 28, e8.
13. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England Journal of Medicine, 327, 1478-1484.
14. Chen, R.C., Chin, M.S., Ng, A.K., Feng, Y., Neuberg, D., Silver, B., Pinkus, G.S., Stevenson, M.A. & Mauch, P.M. (2010) Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. Journal of Clinical Oncology, 28, 136-141.
15. Chera, B.S., Olivier, K., Morris, C.G., Lynch, J.W. & Mendenhall, N.P. (2007) Clinical presentation and outcomes of lymphocyte-predominant h=Hodgkin disease at the University of Florida. American Journal of Clinical Oncology, 30, 601-606.
16. Denham, J.W., Denham, E., Dear, K.B. & Hudson, G.V. (1996) The follicular non-Hodgkin's lymphomas-I. The possibility of cure. European Journal of Cancer, 32A, 470-479.
17. Diehl, V., Sextro, M., Franklin, J., Hansmann, M.L., Harris, N., Jaffe, E., Poppema, S., Harris, M., Franssila, K., van Krieken, J., Marafioti, T., Anagnostopoulos, I. & Stein, H. (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on lymphocyte-predominant Hodgkin's disease. Journal of Clinical Oncology, 17, 776-783.
18. Donaldson, S.S., Link, M.P., Weinstein, H.J., Rai, S.N., Brain, S., Billett, A.L., Hurwitz, C.A., Krasin, M., Kun, L.E., Marcus, K.C., Tarbell, N.J., Young, J.A. & Hudson, M.M. (2007) Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. Journal of Clinical Oncology, 25, 332-337.
19. Duggan, D.B., Petroni, G.R., Johnson, J.L., Glick, J.H., Fisher, R.I., Connors, J.M., Canellos, G.P. & Peterson, B.A. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup Trial. Journal of Clinical Oncology, 21, 607-614.
20. Eichenauer, D.A., Engert, A., Dreyling, M. & ESMO Guidelines Working Group. (2011a) Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22(Suppl 6), vi55-vi58.
21. Eichenauer, D.A., Fuchs, M., Pluetschow, A., Klimm, B., Halbsguth, T., Boll, B., von Tresckow, B., Nogova, L., Borchmann, P. & Engert, A. (2011b) Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood, 118, 4363-4365.
22. Ekstrand, B.C., Lucas, J.B., Horwitz, S.M., Fan, Z., Breslin, S., Hoppe, R.T., Natkunam, Y., Bartlett, N.L. & Horning, S.J. (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood, 101, 4285-4289.
23. El Weshi, A., Akhtar, S., Mourad, W.A., Ajarim, D., Abdelsalm, M., Khafaga, Y., Bazarbashi, S. & Maghfoor, I. (2007) T-cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leukemia & Lymphoma, 48, 1764-1773.
24. Engert, A., Franklin, J., Eich, H.T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Muller, R.P., Muller-Hermelink, H.K., Duhmke, E. & Diehl, V. (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology, 25, 3495-3502.
25. Engert, A., Plutschow, A., Eich, H.T., Lohri, A., Dorken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sokler, M., Ho, A., Rank, A., Ganser, A., Trumper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Kral, Z., Fuchs, M., Muller-Hermelink, H.K., Muller, R.P. & Diehl, V. (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. The New England Journal of Medicine, 363, 640-652.
26. Fanale, M.A., Lai, C., McLaughlin, P., Romaguera, J., Fayad, L., Hagemeister, F., Samaniego, F., Rodriguez, M.A., Neelapu, S.S., Shah, J.J., Kwak, L., Dong, W., Reed, V., Dabaja, B.S., Popat, U. & Younes, A. (2010) Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood (ASH Annual Meeting Abstracts), 116, 2812.
27. Farrell, K., McKay, P. & Leach, M. (2011) Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network. Leukemia & Lymphoma, 52, 1920-1928.
28. Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M.B., Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Van den Neste, E., Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P., Lugtenburg, P.J., Carrie, C., Jaubert, J., Henry-Amar, M. & EORTC-GELA H8 Trial. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. The New England Journal of Medicine, 357, 1916-1927.
29. Feugier, P., Labouyrie, E., Djeridane, M., Jenabian, A., Dubruille, V., Berthou, C., Ghandour, C., Desablens, B., Chait, Y., Casassus, P., Delwail, V., Ifrah, N., Le Mevel, A., Lamy, T., Briere, J., Colonna, P. & Andrieu, J.M. (2004) Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood, 104, 2675-2681.
30. Gilbert, E.S., Stovall, M., Gospodarowicz, M., Van Leeuwen, F.E., Andersson, M., Glimelius, B., Joensuu, T., Lynch, C.F., Curtis, R.E., Holowaty, E., Storm, H., Pukkala, E., van't Veer, M.B., Fraumeni, J.F., Boice, Jr, J.D., Clarke, E.A. & Travis, L.B. (2003) Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiation Research, 159, 161-173.
31. Greiner, T.C., Gascoyne, R.D., Anderson, M.E., Kingma, D.W., Adomat, S.A., Said, J. & Jaffe, E.S. (1996) Nodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood, 88, 657-666.
32. Hall, G.W., Katzilakis, N., Pinkerton, C.R., Nicolin, G., Ashley, S., McCarthy, K., Daw, S., Hewitt, M., Wallace, W.H. & Shankar, A. (2007) Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group Report. British Journal of Haematology, 138, 761-768.
33. Horning, S.J., Bartlett, N.L., Breslin, S., Advani, R.H., Hoppe, R.T., Ekstrand, B.C. & Lucas, J.B. (2007) Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood (ASH Annual Meeting Abstracts), 110, 644.
34. Huang, J.Z., Weisenburger, D.D., Vose, J.M., Greiner, T.C., Aoun, P., Chan, W.C., Lynch, J.C., Bierman, P.J. & Armitage, J.O. (2004) Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leukemia & Lymphoma, 45, 1551-1557.
35. Hutchings, M., Loft, A., Hansen, M., Ralfkiaer, E. & Specht, L. (2006) Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematological Oncology, 24, 146-150.
36. Jackson, C., Sirohi, B., Cunningham, D., Horwich, A., Thomas, K. & Wotherspoon, A. (2010) Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Annals of Oncology, 21, 2061-2068.
37. Jaffe, E.S., Harris, N.L., Vardiman, J., Campo, E. & Arber, D. (2010) Nodular lymphocyte-predominant type of Hodgkin's lymphoma. In: Hematopathology, pp. 436-453. W.B. Saunders, Philadelphia, PA.
38. Josting, A., Rueffer, U., Franklin, J., Sieber, M., Diehl, V. & Engert, A. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the german Hodgkin lymphoma study group. Blood, 96, 1280-1286.
39. Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D. & Hudson, G.V. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet, 341, 1051-1054.
40. Mac Manus, M.P. & Hoppe, R.T. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology, 14, 1282-1290.
41. Mauz-Korholz, C., Gorde-Grosjean, S., Hasenclever, D., Shankar, A., Dorffel, W., Wallace, W.H., Schellong, G., Robert, A., Korholz, D., Oberlin, O., Hall, G.W. & Landman-Parker, J. (2007) Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European Network Group on pediatric Hodgkin lymphoma. Cancer, 110, 179-185.
42. Meyer, R.M., Gospodarowicz, M.K., Connors, J.M., Pearcey, R.G., Wells, W.A., Winter, J.N., Horning, S.J., Dar, A.R., Shustik, C., Stewart, D.A., Crump, M., Djurfeldt, M.S., Chen, B.E., Shepherd, L.E. & NCIC Clinical Trials Group & Eastern Cooperative Oncology Group. (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. The New England Journal of Medicine, 366, 399-408.
43. Nogova, L., Reineke, T., Eich, H.T., Josting, A., Muller-Hermelink, H.K., Wingbermuhle, K., Brillant, C., Gossmann, A., Oertel, J., Bollen, M.V., Muller, R.P., Diehl, V. & Engert, A. (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Annals of Oncology, 16, 1683-1687.
44. Nogova, L., Reineke, T., Brillant, C., Sieniawski, M., Rudiger, T., Josting, A., Bredenfeld, H., Skripnitchenko, R., Muller, R.P., Muller-Hermelink, H.K., Diehl, V., Engert, A. & German Hodgkin Study Group. (2008) Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. Journal of Clinical Oncology, 26, 434-439.
45. O'Brien, M.M., Donaldson, S.S., Balise, R.R., Whittemore, A.S. & Link, M.P. (2010) Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. Journal of Clinical Oncology, 28, 1232-1239.
46. Ohno, T., Huang, J.Z., Wu, G., Park, K.H., Weisenburger, D.D. & Chan, W.C. (2001) The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis. American Journal of Clinical Pathology, 116, 506-511.
47. Orlandi, E., Lazzarino, M., Brusamolino, E., Paulli, M., Astori, C., Magrini, U. & Bernasconi, C. (1997) Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leukemia & Lymphoma, 26, 359-368.
48. Pedersen-Bjergaard, J., Specht, L., Larsen, S.O., Ersboll, J., Struck, J., Hansen, M.M., Hansen, H.H. & Nissen, N.I. (1987) Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet, 2, 83-88.
49. Poppema, S., Kaiserling, E. & Lennert, K. (1979) Hodgkin's disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres-A cytohistological study. Histopathology, 3, 295-308.
50. Rueffer, U., Josting, A., Franklin, J., May, M., Sieber, M., Breuer, K., Engert, A., Diehl, V. & German Hodgkin's Lymphoma Study Group. (2001) Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. Journal of Clinical Oncology, 19, 2026-2032.
51. Savage, K.J., Skinnider, B., Al-Mansour, M., Sehn, L.H., Gascoyne, R.D. & Connors, J.M. (2011) Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood, 118, 4585-4590.
52. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H., Diehl, V. & German Hodgkin's Lymphoma Study Group & Lymphoma Working Party of the European Group for Blood Marrow Transplantation. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
53. Shankar, A., Hall, G.W., Gorde-Grosjean, S., Hasenclever, D., Leblanc, T., Hayward, J., Lambilliotte, A., Daw, S., Perel, Y., McCarthy, K., Lejars, O., Coulomb, A., Oberlin, W.O., Wallace, W.H. & Landman-Parker, J. (2012) Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. European Journal of Cancer, 48, 1700-1706.
54. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) Nodular lymphocyte predominant Hodgkin lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Anonymous, pp. 323-325. IARC, Lyon.
55. Tucker, M.A., Coleman, C.N., Cox, R.S., Varghese, A. & Rosenberg, S.A. (1988) Risk of second cancers after treatment for Hodgkin's disease. The New England Journal of Medicine, 318, 76-81.
56. Unal, A., Sari, I., Deniz, K., Ozkan, M., Kontas, O., Eser, B. & Cetin, M. (2005) Familial nodular lymphocyte predominant Hodgkin lymphoma: successful treatment with CHOP plus rituximab. Leukemia & Lymphoma, 46, 1613-1617.
57. Wickert, R.S., Weisenburger, D.D., Tierens, A., Greiner, T.C. & Chan, W.C. (1995) Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood, 86, 2312-2320.
58. Wilder, R.B., Schlembach, P.J., Jones, D., Chronowski, G.M., Ha, C.S., Younes, A., Hagemeister, F.B., Barista, I., Cabanillas, F. & Cox, J.D. (2002) European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer, 94, 1731-1738.
59. Wirth, A., Yuen, K., Barton, M., Roos, D., Gogna, K., Pratt, G., Macleod, C., Bydder, S., Morgan, G. & Christie, D. (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer, 104, 1221-1229.
60. Wolden, S.L., Chen, L., Kelly, K.M., Herzog, P., Gilchrist, G.S., Thomson, J., Sposto, R., Kadin, M.E., Hutchinson, R.J. & Nachman, J. (2012) Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma - A report from the Children's Oncology Group. Journal of Clinical Oncology, 30, 3174-3180.
61. Xing, K.H., Connors, J.M., Al-Mansour, M., Gascoyne, R.D., Skinnider, B. & Savage, K.J. (2012) The outcome of advanced stage nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) compared to classical Hodgkin's lymphoma (CHL): a matched pair analysis. Blood (ASH Annual Meeting Abstracts), 120, 1531.